Amini: The majority of these patients — except at this time stage 1 — will need systemic therapy as part of their therapy, whether it is in the locally advanced resectable or unresectable case or ...
Amini: From a radiation standpoint, this has changed the landscape of our field. A large proportion of my practice is stage IV disease, where patients who are on these excellent systemic therapies are ...
Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...
For oncologists navigating the rapidly evolving landscape of renal cell carcinoma (RCC), the data presented at the 2026 ASCO ...
Revolution Medicines, Inc. (Nasdaq:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that nine oral and poster ...
Dr. Brian S. Henick, a medical oncologist at Columbia University Irving Medical Center and director of the phase 1 program and translational research in aerodigestive cancers, outlined in an interview ...
KU Leuven Center for Cancer Biology, in collaboration with the Francis Crick Institute, has discovered how cancer cells can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results